Review Evaluates Artificial Intelligence Tools Across Pharmaceutical Discovery and Development

Pharmaceutical research and development continues to confront steep economic and operational hurdles, as creating a single new therapeutic typically costs more than 2.5 billion dollars and demands over a decade of research. Clinical translation remains particularly constrained, with only a small fraction of candidate molecules securing regulatory approval and a meager 2.01 percent of drug development projects ultimately yielding a marketable product. To address these persistent attrition rates, a comprehensive review published in Discover Pharmaceutical Sciences by Shashi Kant, Deepika, and Saheli Roy examines how computational methodologies are reshaping the therapeutic development trajectory. The review details how multidisciplinary artificial intelligence systems—incorporating machine learning, deep learning, natural language processing, reinforcement learning, graph neural networks, and generative models—are applied to bypass historical bottlenecks that impede target validation, compound screening, structural optimization, and clinical investigation.

Traditional discovery frameworks are routinely hampered by sequential friction points, beginning with the laborious identification and biological validation of target molecules and extending through the resource-intensive demands of high-throughput experimental screening. Subsequent iterative optimization cycles designed to elevate potency, biological selectivity, and physiological safety escalate project expenses before candidates reach clinical evaluation. In human trials, recruitment difficulties, trial design constraints, and data collection logistics further undermine development success. The authors outline how artificial intelligence platforms approach these bottlenecks computationally, allowing systems to learn from complex biological and chemical datasets without explicit task-specific programming. Foundational machine learning approaches, including support vector machines and random forests, are employed alongside deep artificial neural networks featuring multilayered architectures inspired by neurological structures, enabling automated feature extraction across high-dimensional experimental data.

In the initial phase of target identification and validation, computational models integrate diverse biological layers, including genomics, proteomics, electronic health records, and specialized public repositories such as DrugBank, PubChem, the Antibiotic Combination DataBase, and the Antibiotic Adjuvant DataBase. Supervised classification tools like support vector machines and random forest ensembles process labeled datasets encompassing gene expression profiles and single-nucleotide polymorphisms to evaluate disease susceptibility and predict risk. Concurrently, unsupervised clustering and dimensionality reduction algorithms group genes sharing parallel expression signatures to uncover novel disease subtypes without requiring pre-existing labels. Deep learning architectures, including convolutional neural networks and recurrent neural networks, analyze complex proteomic structures and interaction networks, with empirical datasets spanning 10,000 to 15,000 entries utilized to interrogate critical targets such as the SARS-CoV-2 main protease for antiviral development and the human Ether-à-go-go-Related Gene for cardiotoxic liabilities.

Moving from target identification to candidate screening and lead discovery, computational platforms replace or supplement physical high-throughput screening through automated virtual evaluation. Quantitative structure–activity relationship models predict the biological affinity and functional activity of molecules based directly on chemical structures, allowing research teams to screen and prioritize vast libraries while minimizing experimental resource expenditure. For lead optimization, predictive models evaluate essential physicochemical properties, including aqueous solubility, molecular stability, and bioavailability. The authors note that quantitative structure–activity relationship investigations frequently leverage datasets containing 1,000 to 5,000 curated data points to predict water solubility, while deep learning architectures simulate compound stability across varying environmental conditions. To support predictive training for protein function, public repositories such as the UniProt Consortium and the Protein Data Bank supply sequence information across diverse species, which undergoes systematic batch downloading, data cleaning, and preprocessing before algorithmic integration.

Preclinical characterization is further augmented by computational modeling of pharmacokinetics, pharmacodynamics, and toxicological profiles. Deep neural networks analyze chemical structural features to predict fundamental absorption, distribution, metabolism, excretion, and toxicity parameters, including compound transport across biological membranes and physiological distribution patterns. By learning complex associations between structural motifs and biological endpoints, machine learning models anticipate adverse drug reactions and off-target toxicities, allowing investigators to eliminate hazardous molecules before embarking on expensive animal studies or clinical trials. When development progresses to human testing, algorithms evaluate historical trial records to optimize protocols, select clinically meaningful primary endpoints, refine statistical power calculations, and determine optimal cohort sizes. AI platforms also assist patient recruitment via targeted outreach strategies, while real-time analytical tools monitor patient data streams during active trials to detect early safety signals, flag unexpected adverse events, and guide adaptive protocol adjustments.

The technical architectures powering these pharmacological workflows span multiple computational disciplines, each addressing specific structural and mathematical properties of biological systems. Supervised learning pipelines rely on verified ground truth to forecast binding efficacy or adverse events, whereas unsupervised algorithms discover hidden clusters in unannotated chemical or genetic libraries. Gradient boosting machines construct robust predictive models by aggregating multiple weak learners, complementing support vector machines that determine optimal classification boundaries in high-dimensional feature spaces. For structural analysis, convolutional neural networks process spatial representations, evaluating molecular structures mapped as two-dimensional topologies or three-dimensional point clouds to predict protein-ligand binding affinities. Conversely, recurrent neural networks leverage sequential architectures to process linear biological strings, modeling protein primary sequences, tracing biochemical reaction cascades, and generating novel drug-like molecular entities.

Natural language processing models provide specialized capabilities for mining vast volumes of unstructured biomedical literature, patent filings, and clinical documentation. Advanced transformer frameworks utilize self-attention mechanisms to evaluate long-range contextual dependencies across sequential information, processing full data inputs in parallel rather than sequentially as in recurrent architectures. Applying transformer designs like BERT, GPT, and T5 to biological sequences has enabled the development of Protein Language Models, which treat amino acid chains as biological text. Pretrained systems, including Evolutionary Scale Modeling-2 and ProtGPT2, support transfer learning for structure prediction, function annotation, and de novo design, with Meta AI’s ESM-2 utilizing 15 billion parameters to predict three-dimensional protein structures directly from primary sequences. Other computational variants, such as OmegaFold, incorporate geometric awareness, while cheminformatics tools including RDKit and ChemDes compute circular Extended Connectivity Fingerprints, path-based fingerprints, and three-dimensional molecular descriptors to encode chemical functional groups for screening.

Beyond sequence and vector representations, graph neural networks process molecular information in non-Euclidean spaces where atoms function as graph nodes and chemical bonds constitute connecting edges. Through iterative message-passing mechanisms, nodes aggregate structural and chemical information from neighboring nodes to construct local and global molecular representations. Specialized architectures including Graph Convolutional Networks, Graph Attention Networks, and GraphSAGE support inductive learning and neighbor prioritization, though deep graph models continue to face technical limitations related to over-smoothing and computational scaling on massive graphs. Complementing graph networks, reinforcement learning frames lead optimization as a formal decision-making process, where an autonomous computational agent iteratively modifies molecular structures or adjusts dosing parameters to maximize a composite reward function balancing therapeutic efficacy against toxicity. Similarly, evolutionary algorithms simulate natural selection principles through iterative mutation and fitness evaluation, generating optimized structural candidates across wide chemical spaces.

Generative artificial intelligence frameworks, including generative adversarial networks comprising competing generator and discriminator networks, synthesize novel molecular structures and generate realistic synthetic data for medical imaging, super-resolution enhancement, and model augmentation. Within real-world deployment, platforms such as DiffDock implement diffusion models for protein-ligand docking, MoleculeGen facilitates molecular generation, and commercial platforms from Atomwise and BenevolentAI evaluate biological datasets to discover candidates for challenging pathologies such as Ebola and COVID-19. In the area of therapeutic repurposing, computational platforms predict new indications for established molecules, exemplified by the identification of baricitinib, an oral Janus kinase inhibitor approved for rheumatoid arthritis, as an effective therapy for COVID-19. Specialized repurposing systems like DeepPurpose utilize customizable deep architectures to score drug-target interactions, while MultiDCP integrates molecular structures and gene expression data. In active clinical pipelines, companies like Exscientia advanced six AI-designed molecules into human trials by 2024 across oncology, immunology, and psychiatric indications.

Despite widespread algorithmic progress, the authors emphasize that substantial technical and operational limitations impede the seamless integration of artificial intelligence into pharmaceutical workflows. The availability of high-quality, standardized, and accurately annotated training data remains a critical bottleneck, as heterogeneous datasets drawn from incompatible biological assays, divergent chemical formats, and inconsistent clinical trials require complex curation and harmonization. Systemic biases embedded within historical training datasets threaten model generalizability, as algorithms trained on narrow demographic cohorts or specific disease subsets can produce erroneous predictions when applied to broader populations. Furthermore, many deep neural networks function as opaque black boxes, creating interpretability challenges that complicate mechanistic validation and hinder the regulatory trust required for clinical translation, where transparent reasoning is essential to safeguard patient welfare and assign professional accountability.

Institutional and regulatory integration poses additional barriers, as traditional pharmaceutical enterprises operate under highly structured validation protocols that adapt slowly to algorithmic workflows. Implementing computational platforms demands major restructuring of technological infrastructure, workflow standards, and institutional expertise, alongside unresolved concerns regarding proprietary intellectual property, patient data confidentiality, and workforce disruption. Ethical considerations are equally pressing; a cited survey of pharmacy professionals in the Middle East and North Africa documented prominent concerns regarding lack of legal regulation (67.0 percent), potential job displacement (62.9 percent), patient data privacy (58.9 percent), and cybersecurity threats (58.9 percent). In clinical environments, using patient records and digital twins introduces privacy vulnerabilities and consent complexities, while drug repurposing initiatives frequently encounter commercial disincentives from weak method-of-use patent protections and demanding regulatory requirements for supplemental clinical trials.

Looking toward future technical trajectories, the review identifies emerging paradigms poised to enhance algorithmic precision, including the convergence of artificial intelligence with decentralized blockchain architectures and Internet of Things monitoring to safeguard clinical data integrity. Advanced sequence modeling alternatives to standard transformers, such as State Space Models exemplified by Hyena and Evo, demonstrate improved computational efficiency and scalability across long-context biological sequences through novel gating and recurrent mechanisms. Furthermore, modern multi-omics integration—uniting genomics, transcriptomics, proteomics, metabolomics, and epigenomics through advanced machine learning and network analysis—is uncovering multidimensional biomarkers across oncology, cardiology, and neurology. The authors conclude that fully realizing the clinical benefits of computational drug development will require established benchmarking protocols, transparent model architectures, evolving regulatory oversight, and sustained cross-disciplinary collaboration between life scientists and computational researchers.

Subject of Research: Artificial intelligence applications, limitations, and real-world implementations across drug discovery and development

Article Title: Artificial intelligence in drug discovery and development: transforming challenges into opportunities

Article References: Kant, S., Deepika, & Roy, S. (2025). Artificial intelligence in drug discovery and development: transforming challenges into opportunities. Discover Pharmaceutical Sciences, 1(1), Article 7. https://doi.org/10.1007/s44395-025-00007-3

Image Credits: AI Generated

DOI: 10.1007/s44395-025-00007-3

Keywords: Artificial Intelligence, Drug Discovery, Machine Learning, Deep Learning, Protein Language Models, Graph Neural Networks, Pharmaceutical Sciences, Clinical Trials, Artificial, intelligence, drug, discovery